Table of Content

1. Executive Summary
1.1. Global Myasthenia Gravis Treatment Market Snapshot, 2025 and 2032
1.2. Market Opportunity Assessment, 2025 – 2032, US$ Bn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overviews
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global Sectorial Outlook
2.3.2. Global GDP Growth Outlook
2.3.3. Global Healthcare Spending Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors – Relevance and Impact
3. Value Added Insights
3.1. Drug Adoption Analysis
3.2. Value Chain Analysis
3.2.1. List of End-user/Marketplaces
3.2.1.1. Retail
3.2.1.2. E-Commerce
3.2.2. List of End User (Industry)
3.3. Key Deals and Mergers
3.4. PESTLE Analysis
3.5. Porter’s Five Force Analysis
4. Global Myasthenia Gravis Treatment Market Outlook: Historical (2019 – 2023) and Forecast (2025 – 2032)
4.1. Key Highlights
4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Bn) Analysis and Forecast
4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2023
4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025–2032
4.3. Global Myasthenia Gravis Treatment Market Outlook: Drug Class
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Bn) Analysis, By Drug Class, 2019 – 2023
4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 – 2032
4.3.3.1. Cholinesterase Inhibitors
4.3.3.2. Corticosteroids
4.3.3.3. Immunosuppressants
4.3.3.4. IVIg
4.3.3.5. Monoclonal Antibodies
4.3.4. Market Attractiveness Analysis: Drug Class
4.4. Global Myasthenia Gravis Treatment Market Outlook: Distribution Channel
4.4.1. Introduction / Key Findings
4.4.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019 – 2023
4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 – 2032
4.4.3.1. Hospital Pharmacies
4.4.3.2. Retail Pharmacies
4.4.3.3. Online Pharmacies
4.4.4. Market Attractiveness Analysis: Distribution Channel
5. Global Myasthenia Gravis Treatment Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019 – 2023
5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025 – 2032
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Myasthenia Gravis Treatment Market Outlook: Historical (2019 – 2023) and Forecast (2025 – 2032)
6.1. Key Highlights
6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 – 2023
6.2.1. By Country
6.2.2. By Drug Class
6.2.3. By Distribution Channel
6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 – 2032
6.3.1. U.S.
6.3.2. Canada
6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 – 2032
6.4.1. Cholinesterase Inhibitors
6.4.2. Corticosteroids
6.4.3. Immunosuppressants
6.4.4. IVIg
6.4.5. Monoclonal Antibodies
6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 – 2032
6.5.1. Hospital Pharmacies
6.5.2. Retail Pharmacies
6.5.3. Online Pharmacies
6.6. Market Attractiveness Analysis
7. Europe Myasthenia Gravis Treatment Market Outlook: Historical (2019 – 2023) and Forecast (2025 – 2032)
7.1. Key Highlights
7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 – 2023
7.2.1. By Country
7.2.2. By Drug Class
7.2.3. By Distribution Channel
7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 – 2032
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Russia
7.3.7. Türkiye
7.3.8. Rest of Europe
7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 – 2032
7.4.1. Cholinesterase Inhibitors
7.4.2. Corticosteroids
7.4.3. Immunosuppressants
7.4.4. IVIg
7.4.5. Monoclonal Antibodies
7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 – 2032
7.5.1. Hospital Pharmacies
7.5.2. Retail Pharmacies
7.5.3. Online Pharmacies
7.6. Market Attractiveness Analysis
8. East Asia Myasthenia Gravis Treatment Market Outlook: Historical (2019 – 2023) and Forecast (2025 – 2032)
8.1. Key Highlights
8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 – 2023
8.2.1. By Country
8.2.2. By Drug Class
8.2.3. By Distribution Channel
8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 – 2032
8.3.1. China
8.3.2. Japan
8.3.3. South Korea
8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 – 2032
8.4.1. Cholinesterase Inhibitors
8.4.2. Corticosteroids
8.4.3. Immunosuppressants
8.4.4. IVIg
8.4.5. Monoclonal Antibodies
8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 – 2032
8.5.1. Hospital Pharmacies
8.5.2. Retail Pharmacies
8.5.3. Online Pharmacies
8.6. Market Attractiveness Analysis
9. South Asia and Oceania Myasthenia Gravis Treatment Market Outlook: Historical (2019 – 2023) and Forecast (2025 – 2032)
9.1. Key Highlights
9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 – 2023
9.2.1. By Country
9.2.2. By Drug Class
9.2.3. By Distribution Channel
9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 – 2032
9.3.1. India
9.3.2. Southeast Asia
9.3.3. ANZ
9.3.4. Rest of South Asia & Oceania
9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 – 2032
9.4.1. Cholinesterase Inhibitors
9.4.2. Corticosteroids
9.4.3. Immunosuppressants
9.4.4. IVIg
9.4.5. Monoclonal Antibodies
9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 – 2032
9.5.1. Hospital Pharmacies
9.5.2. Retail Pharmacies
9.5.3. Online Pharmacies
9.6. Market Attractiveness Analysis
10. Latin America Myasthenia Gravis Treatment Market Outlook: Historical (2019 – 2023) and Forecast (2025 – 2032)
10.1. Key Highlights
10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 – 2023
10.2.1. By Country
10.2.2. By Drug Class
10.2.3. By Distribution Channel
10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 – 2032
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 – 2032
10.4.1. Cholinesterase Inhibitors
10.4.2. Corticosteroids
10.4.3. Immunosuppressants
10.4.4. IVIg
10.4.5. Monoclonal Antibodies
10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 – 2032
10.5.1. Hospital Pharmacies
10.5.2. Retail Pharmacies
10.5.3. Online Pharmacies
10.6. Market Attractiveness Analysis
11. Middle East & Africa Myasthenia Gravis Treatment Market Outlook: Historical (2019 – 2023) and Forecast (2025 – 2032)
11.1. Key Highlights
11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 – 2023
11.2.1. By Country
11.2.2. By Drug Class
11.2.3. By Distribution Channel
11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 – 2032
11.3.1. GCC Countries
11.3.2. Egypt
11.3.3. South Africa
11.3.4. Northern Africa
11.3.5. Rest of Middle East & Africa
11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 – 2032
11.4.1. Cholinesterase Inhibitors
11.4.2. Corticosteroids
11.4.3. Immunosuppressants
11.4.4. IVIg
11.4.5. Monoclonal Antibodies
11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 – 2032
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2025
12.2. Market Structure
12.2.1. Competition Intensity Mapping By Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
12.3.1. Alexion Pharmaceutical Inc.
12.3.1.1. Overview
12.3.1.2. Segments and Products
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. Grifols SA
12.3.3. Avadel Pharmaceuticals plc.
12.3.4. Novartis AG
12.3.5. Pfizer; Inc.
12.3.6. AbbVie Inc.
12.3.7. F. Hoffmann-La Roche Ltd.
12.3.8. GlaxoSmithKline plc
12.3.9. Bausch Health Companies Inc.
12.3.10. Shire plc.
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations